Insilico Medicine has granted TaiGen Biotechnology exclusive rights to develop and commercialise ISM4808, a potential best-in-class oral PHD inhibitor, in Greater China. The candidate, nominated by Insilico's generative AI platform Chemistry42, is intended for the treatment of anaemia associated with chronic kidney disease (CKD). Under the agreement, Insilico is eligible for an upfront payment, development and sales milestone payments, and tiered royalties, in a deal valued at tens of millions of USD.

ISM4808 works by stabilising hypoxia-inducible factors (HIF) to stimulate erythropoietin production and improve iron utilisation. The candidate demonstrated strong efficacy and favourable drug-like properties in pre-clinical studies, leading to IND approval in China in 2023. TaiGen's clinical development expertise and commercial resources in Greater China, a region with a significant and growing CKD patient population, are expected to accelerate the program. The partnership represents a key step in translating Insilico's AI-discovered pipeline into potential therapies for patients.

According to PharmCube's NextBiopharm® database, Insilico is increasing its out-licensing activity, with eight deals so far in 2025. Click here to request a free trial for NextBiopharm®.